by Indication (Influenza, Rotavirus, DTP, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccines, Live Attenuated Vaccines), and Valence (Multivalent, Monovalent Vaccines) Forecast to 2027 , published by Meticulous Research
®, the vaccines market is expected to grow at a CAGR of 12.5% from 2020 to 2027 to reach $108.02 billion by 2027.
The high prevalence of diseases, increasing government initiatives towards immunization, technological advancements in vaccine production, the strong pipeline for vaccines globally, and the emergence of the COVID-19 pandemic are the key factors expected to propel the growth of the vaccines market. Besides, the increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market.
COVID-19 survivors tend to have a roughly tenfold increase in protection against the virus, according to a government-funded study published Wednesday. Why it matters: There have been some documented cases of reinfection leading to concern survivors don't gain any immunity. While there remain questions on how much or how long immunity lasts and what the impact of variants will be, this large set of observational data bolsters evidence there's some protection.Get market news worthy of your time with Axios Markets. Subscribe for free.The latest: The study, published in JAMA Internal Medicine, examined commercial SARS-CoV-2 antibody test data from 3.2 million U.S. patients from Jan. 1 and Aug. 23, 2020.Out of those who had tested antibody-negative initially and were later tested for active infection, they found 3% were positive for SARS-CoV-2 90 or more days later.Out of those who were antibody-positive initially and were later tested for active infection, they found only 0.3% w
F. Hoffmann-La Roche Ltd
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
Special approval from German Federal Institute for Drugs and Medical Devices (BfArM) enables home use of a SARS-CoV-2 Rapid Antigen Test using a simple nasal swab
The test will be widely available in pharmacies across Germany
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SARS-CoV-2 Rapid Antigen Test using a simple nasal swab for patient self-testing in Germany.
UVA antibody testing proposes many Virginians vulnerable to COVID-19
and last updated 2021-02-24 08:11:19-05
CHARLOTTESVILLE, Va. - As Americans across the country are on the hunt towards herd immunity to end the COVID-19 pandemic, researchers at the University of Virginia are revealing COVID-19 antibody testing done around the state.
âAntibodies are a way to see additionally about how much spread has occurred that we don t know about,â Dr. Eric Houpt, Professor and Chief of Infectious Diseases at UVA Health.
âThe purpose of this study was an early assessment of how much COVID had spread after that first wave back in spring 2020.â